Gilead Drug Fails AIDS Prevention Trial

Luke Timmerman4/18/11

Researchers have halted a study of Gilead Sciences’ emtricitabine tenofovir (Truvada) after it failed to show in a study that it can help prevent HIV infections among women in Africa, according to a report from the Associated Press. The finding was disappointing, the AP notes, because a previous study showed that the drug from Foster City, CA-based Gilead (NASDAQ: GILD) was able to prevent HIV infections in gay and bisexual men when it was given with condoms, counseling, and other prevention services.

Luke Timmerman is the National Biotech Editor of Xconomy. E-mail him at ltimmerman@xconomy.com Follow @